Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cachexia | 11 | 2019 | 161 | 3.150 |
Why?
|
| Palliative Care | 28 | 2023 | 2037 | 2.060 |
Why?
|
| Neoplasms | 43 | 2024 | 15193 | 1.760 |
Why?
|
| Hypogonadism | 6 | 2019 | 257 | 1.740 |
Why?
|
| Anorexia | 5 | 2023 | 143 | 1.640 |
Why?
|
| Antiemetics | 2 | 2023 | 125 | 1.560 |
Why?
|
| Terminal Care | 11 | 2019 | 447 | 1.510 |
Why?
|
| Testosterone | 8 | 2019 | 619 | 1.310 |
Why?
|
| Analgesics, Opioid | 14 | 2023 | 1371 | 1.250 |
Why?
|
| Substance-Related Disorders | 4 | 2024 | 524 | 1.160 |
Why?
|
| Psychological Tests | 1 | 2024 | 131 | 0.910 |
Why?
|
| Vomiting | 2 | 2023 | 354 | 0.910 |
Why?
|
| Nausea | 2 | 2023 | 525 | 0.890 |
Why?
|
| Cancer Pain | 6 | 2020 | 312 | 0.870 |
Why?
|
| Family | 4 | 2015 | 736 | 0.850 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2023 | 134 | 0.790 |
Why?
|
| Morphine | 4 | 2023 | 308 | 0.760 |
Why?
|
| Hydrazines | 2 | 2021 | 208 | 0.750 |
Why?
|
| Self Report | 1 | 2024 | 756 | 0.720 |
Why?
|
| Ghrelin | 1 | 2019 | 79 | 0.700 |
Why?
|
| Tobacco Use | 2 | 2018 | 54 | 0.680 |
Why?
|
| Adaptation, Psychological | 3 | 2024 | 764 | 0.670 |
Why?
|
| Hydrocortisone | 4 | 2014 | 388 | 0.610 |
Why?
|
| Triazoles | 1 | 2021 | 617 | 0.590 |
Why?
|
| Stress, Psychological | 2 | 2013 | 1000 | 0.500 |
Why?
|
| Attitude | 1 | 2015 | 159 | 0.490 |
Why?
|
| Body Composition | 5 | 2019 | 595 | 0.490 |
Why?
|
| Insulin Resistance | 1 | 2019 | 731 | 0.480 |
Why?
|
| Referral and Consultation | 4 | 2014 | 899 | 0.460 |
Why?
|
| Hormone Replacement Therapy | 3 | 2014 | 205 | 0.460 |
Why?
|
| Fentanyl | 4 | 2022 | 148 | 0.460 |
Why?
|
| Pain | 6 | 2023 | 1658 | 0.450 |
Why?
|
| Vitamin D | 2 | 2014 | 261 | 0.450 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 527 | 0.450 |
Why?
|
| Patient Preference | 1 | 2015 | 218 | 0.440 |
Why?
|
| Fluid Therapy | 2 | 2015 | 182 | 0.420 |
Why?
|
| Attitude to Death | 1 | 2013 | 100 | 0.420 |
Why?
|
| Dehydration | 1 | 2012 | 87 | 0.420 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2012 | 84 | 0.420 |
Why?
|
| Medical Staff, Hospital | 1 | 2012 | 118 | 0.410 |
Why?
|
| Fatigue | 3 | 2021 | 1239 | 0.400 |
Why?
|
| Energy Intake | 3 | 2019 | 515 | 0.400 |
Why?
|
| Parenteral Nutrition | 1 | 2012 | 207 | 0.390 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2011 | 59 | 0.390 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 115 | 0.370 |
Why?
|
| Patient Participation | 2 | 2013 | 446 | 0.350 |
Why?
|
| Ambulatory Care | 2 | 2021 | 554 | 0.350 |
Why?
|
| Male | 36 | 2024 | 123000 | 0.350 |
Why?
|
| Gastrostomy | 2 | 2021 | 180 | 0.350 |
Why?
|
| Nutritional Support | 3 | 2019 | 80 | 0.350 |
Why?
|
| Middle Aged | 31 | 2024 | 86204 | 0.340 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 672 | 0.330 |
Why?
|
| Nicotine | 1 | 2011 | 244 | 0.330 |
Why?
|
| Tobacco Use Disorder | 1 | 2011 | 284 | 0.330 |
Why?
|
| Humans | 56 | 2024 | 261506 | 0.330 |
Why?
|
| Decompression, Surgical | 1 | 2009 | 143 | 0.320 |
Why?
|
| Alcoholism | 1 | 2011 | 285 | 0.320 |
Why?
|
| Megestrol Acetate | 1 | 2007 | 29 | 0.310 |
Why?
|
| Energy Metabolism | 3 | 2019 | 992 | 0.300 |
Why?
|
| Weight Loss | 3 | 2018 | 627 | 0.300 |
Why?
|
| Adrenal Insufficiency | 1 | 2007 | 49 | 0.290 |
Why?
|
| Aged | 26 | 2023 | 70117 | 0.290 |
Why?
|
| Caregivers | 1 | 2013 | 677 | 0.290 |
Why?
|
| Intestinal Obstruction | 1 | 2009 | 202 | 0.290 |
Why?
|
| Prospective Studies | 10 | 2024 | 12873 | 0.280 |
Why?
|
| Delirium | 3 | 2018 | 207 | 0.280 |
Why?
|
| Female | 32 | 2024 | 141928 | 0.270 |
Why?
|
| Hospitalization | 3 | 2019 | 2083 | 0.270 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 5061 | 0.260 |
Why?
|
| Electric Impedance | 2 | 2016 | 100 | 0.260 |
Why?
|
| Surveys and Questionnaires | 6 | 2024 | 5687 | 0.250 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 7789 | 0.240 |
Why?
|
| Adult | 24 | 2021 | 77950 | 0.240 |
Why?
|
| Alprazolam | 1 | 2023 | 8 | 0.230 |
Why?
|
| Off-Label Use | 1 | 2023 | 46 | 0.220 |
Why?
|
| Quality of Life | 6 | 2023 | 4532 | 0.220 |
Why?
|
| Thyrotropin | 2 | 2014 | 119 | 0.220 |
Why?
|
| Pain Measurement | 3 | 2018 | 953 | 0.210 |
Why?
|
| Palliative Medicine | 1 | 2021 | 23 | 0.200 |
Why?
|
| Oxymorphone | 1 | 2021 | 9 | 0.200 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 1390 | 0.190 |
Why?
|
| Substance Abuse Detection | 1 | 2020 | 64 | 0.190 |
Why?
|
| Outpatients | 2 | 2023 | 462 | 0.180 |
Why?
|
| Acupuncture Therapy | 1 | 2021 | 89 | 0.180 |
Why?
|
| Texas | 5 | 2015 | 6311 | 0.180 |
Why?
|
| Cancer Care Facilities | 3 | 2019 | 884 | 0.180 |
Why?
|
| Dyspnea | 2 | 2022 | 416 | 0.180 |
Why?
|
| Young Adult | 11 | 2021 | 21445 | 0.180 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 4314 | 0.180 |
Why?
|
| Aged, 80 and over | 15 | 2019 | 29902 | 0.180 |
Why?
|
| Sarcopenia | 2 | 2018 | 110 | 0.170 |
Why?
|
| Dietary Carbohydrates | 1 | 2019 | 134 | 0.170 |
Why?
|
| Cost of Illness | 2 | 2014 | 498 | 0.170 |
Why?
|
| Tranquilizing Agents | 1 | 2018 | 6 | 0.160 |
Why?
|
| Benzodiazepines | 1 | 2019 | 170 | 0.160 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2018 | 19 | 0.160 |
Why?
|
| Dietary Proteins | 1 | 2019 | 241 | 0.160 |
Why?
|
| Androgens | 2 | 2014 | 511 | 0.160 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 218 | 0.150 |
Why?
|
| Psychomotor Agitation | 1 | 2018 | 78 | 0.150 |
Why?
|
| Retrospective Studies | 13 | 2021 | 37905 | 0.150 |
Why?
|
| Nutrition Assessment | 1 | 2018 | 169 | 0.150 |
Why?
|
| Appetite Stimulants | 1 | 2017 | 14 | 0.150 |
Why?
|
| Electrodiagnosis | 1 | 2016 | 19 | 0.150 |
Why?
|
| Walking | 1 | 2019 | 277 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 2403 | 0.150 |
Why?
|
| Communication | 3 | 2015 | 876 | 0.140 |
Why?
|
| Death | 2 | 2015 | 119 | 0.140 |
Why?
|
| Serum Albumin | 2 | 2014 | 257 | 0.140 |
Why?
|
| Administration, Cutaneous | 3 | 2016 | 141 | 0.140 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 483 | 0.140 |
Why?
|
| Cisplatin | 1 | 2023 | 2432 | 0.130 |
Why?
|
| Malnutrition | 1 | 2018 | 218 | 0.130 |
Why?
|
| Survival Analysis | 5 | 2019 | 9180 | 0.130 |
Why?
|
| Biomarkers | 2 | 2018 | 5047 | 0.130 |
Why?
|
| Basal Metabolism | 1 | 2014 | 88 | 0.120 |
Why?
|
| Inhalation | 1 | 2014 | 42 | 0.120 |
Why?
|
| France | 1 | 2014 | 108 | 0.120 |
Why?
|
| Hand Strength | 1 | 2014 | 65 | 0.120 |
Why?
|
| Inflammation | 2 | 2014 | 2522 | 0.120 |
Why?
|
| Nutritional Status | 2 | 2015 | 337 | 0.120 |
Why?
|
| Community Participation | 1 | 2014 | 53 | 0.120 |
Why?
|
| Vitamin B 12 | 1 | 2014 | 73 | 0.120 |
Why?
|
| Terminology as Topic | 2 | 2013 | 414 | 0.120 |
Why?
|
| Expressed Emotion | 1 | 2013 | 22 | 0.110 |
Why?
|
| Appetite | 1 | 2013 | 73 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 3719 | 0.110 |
Why?
|
| Physicians | 1 | 2021 | 882 | 0.110 |
Why?
|
| Causality | 1 | 2013 | 178 | 0.110 |
Why?
|
| Melatonin | 1 | 2013 | 46 | 0.110 |
Why?
|
| Terminally Ill | 1 | 2013 | 91 | 0.110 |
Why?
|
| Antipsychotic Agents | 1 | 2016 | 414 | 0.110 |
Why?
|
| Physical Examination | 1 | 2014 | 299 | 0.110 |
Why?
|
| Physician-Patient Relations | 2 | 2021 | 792 | 0.110 |
Why?
|
| Hemoglobins | 1 | 2014 | 477 | 0.100 |
Why?
|
| Hypothyroidism | 1 | 2012 | 204 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1303 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2023 | 6869 | 0.090 |
Why?
|
| Dexamethasone | 2 | 2022 | 1450 | 0.090 |
Why?
|
| Thyroid Gland | 1 | 2012 | 355 | 0.090 |
Why?
|
| Survival | 1 | 2010 | 177 | 0.090 |
Why?
|
| Acute Disease | 1 | 2015 | 2422 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2014 | 621 | 0.090 |
Why?
|
| Pain, Intractable | 1 | 2011 | 171 | 0.090 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2009 | 51 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2022 | 2588 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2014 | 795 | 0.080 |
Why?
|
| Pyrroles | 1 | 2012 | 576 | 0.080 |
Why?
|
| Prognosis | 4 | 2019 | 21713 | 0.080 |
Why?
|
| Colectomy | 1 | 2009 | 288 | 0.070 |
Why?
|
| Haloperidol | 2 | 2018 | 64 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 1270 | 0.070 |
Why?
|
| Indoles | 1 | 2012 | 1009 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 6207 | 0.070 |
Why?
|
| Comorbidity | 1 | 2013 | 2352 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2011 | 1171 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 1248 | 0.060 |
Why?
|
| Decision Making | 1 | 2012 | 1287 | 0.060 |
Why?
|
| Patient Care Planning | 2 | 2016 | 297 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2007 | 629 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 4938 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2007 | 1544 | 0.060 |
Why?
|
| Levorphanol | 1 | 2023 | 14 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1945 | 0.060 |
Why?
|
| Incidence | 1 | 2013 | 5673 | 0.050 |
Why?
|
| Survival Rate | 2 | 2013 | 12221 | 0.050 |
Why?
|
| Hydromorphone | 1 | 2022 | 58 | 0.050 |
Why?
|
| Pain Management | 2 | 2019 | 668 | 0.050 |
Why?
|
| Moxibustion | 1 | 2021 | 9 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 2315 | 0.050 |
Why?
|
| Treatment Outcome | 6 | 2022 | 32848 | 0.050 |
Why?
|
| Urine | 1 | 2020 | 143 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 2326 | 0.050 |
Why?
|
| Oral Sprays | 1 | 2019 | 8 | 0.040 |
Why?
|
| Administration, Sublingual | 1 | 2019 | 25 | 0.040 |
Why?
|
| Walk Test | 1 | 2019 | 43 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2019 | 191 | 0.040 |
Why?
|
| Physical Exertion | 1 | 2019 | 113 | 0.040 |
Why?
|
| Perception | 1 | 2021 | 350 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2021 | 429 | 0.040 |
Why?
|
| Drug Overdose | 1 | 2019 | 81 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 544 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2019 | 209 | 0.040 |
Why?
|
| Counseling | 1 | 2021 | 381 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 3022 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 4320 | 0.040 |
Why?
|
| Lorazepam | 1 | 2018 | 40 | 0.040 |
Why?
|
| Risk Factors | 1 | 2013 | 17523 | 0.030 |
Why?
|
| Marital Status | 1 | 2015 | 98 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 918 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2014 | 175 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 403 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 1183 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 929 | 0.030 |
Why?
|
| Psychometrics | 1 | 2018 | 937 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 7551 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 1085 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 2803 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 551 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2021 | 1423 | 0.030 |
Why?
|
| Thyroxine | 1 | 2012 | 116 | 0.030 |
Why?
|
| Patients | 1 | 2014 | 245 | 0.030 |
Why?
|
| Hospice Care | 1 | 2012 | 156 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2012 | 587 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 748 | 0.020 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2010 | 51 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 829 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 589 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2010 | 257 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 866 | 0.020 |
Why?
|
| Antioxidants | 1 | 2013 | 507 | 0.020 |
Why?
|
| Time Factors | 2 | 2014 | 12926 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 3472 | 0.020 |
Why?
|
| Adolescent | 3 | 2015 | 31252 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 4298 | 0.020 |
Why?
|
| Pneumonia | 1 | 2015 | 751 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2013 | 785 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2011 | 289 | 0.020 |
Why?
|
| Overweight | 1 | 2012 | 484 | 0.020 |
Why?
|
| Body Weight | 1 | 2013 | 1293 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 15694 | 0.020 |
Why?
|
| Medical Audit | 1 | 2008 | 188 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8865 | 0.020 |
Why?
|
| Professional-Family Relations | 1 | 2008 | 134 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 5377 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 4892 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2012 | 2203 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2007 | 14289 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 3890 | 0.020 |
Why?
|
| United States | 1 | 2021 | 15433 | 0.010 |
Why?
|
| Depression | 1 | 2013 | 1715 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2012 | 6100 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 14889 | 0.010 |
Why?
|
| Obesity | 1 | 2012 | 2884 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 2576 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 4975 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2010 | 2138 | 0.010 |
Why?
|
| Carcinoma | 1 | 2010 | 2578 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 4557 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 5767 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2010 | 5319 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 11538 | 0.000 |
Why?
|